JP2025505546A5 - - Google Patents

Info

Publication number
JP2025505546A5
JP2025505546A5 JP2024545105A JP2024545105A JP2025505546A5 JP 2025505546 A5 JP2025505546 A5 JP 2025505546A5 JP 2024545105 A JP2024545105 A JP 2024545105A JP 2024545105 A JP2024545105 A JP 2024545105A JP 2025505546 A5 JP2025505546 A5 JP 2025505546A5
Authority
JP
Japan
Prior art keywords
receptor protein
chimeric receptor
domain
cells
genetically modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024545105A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025505546A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/061966 external-priority patent/WO2023150698A2/en
Publication of JP2025505546A publication Critical patent/JP2025505546A/ja
Publication of JP2025505546A5 publication Critical patent/JP2025505546A5/ja
Pending legal-status Critical Current

Links

JP2024545105A 2022-02-04 2023-02-03 キメラilt受容体組成物及び方法 Pending JP2025505546A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263306514P 2022-02-04 2022-02-04
US63/306,514 2022-02-04
PCT/US2023/061966 WO2023150698A2 (en) 2022-02-04 2023-02-03 Chimeric ilt receptor compositions and methods

Publications (2)

Publication Number Publication Date
JP2025505546A JP2025505546A (ja) 2025-02-28
JP2025505546A5 true JP2025505546A5 (cg-RX-API-DMAC7.html) 2026-02-10

Family

ID=87553009

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024545105A Pending JP2025505546A (ja) 2022-02-04 2023-02-03 キメラilt受容体組成物及び方法

Country Status (8)

Country Link
US (2) US12269861B2 (cg-RX-API-DMAC7.html)
EP (1) EP4473006A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025505546A (cg-RX-API-DMAC7.html)
KR (1) KR20240156654A (cg-RX-API-DMAC7.html)
CN (1) CN119053618A (cg-RX-API-DMAC7.html)
AU (1) AU2023216270A1 (cg-RX-API-DMAC7.html)
CA (1) CA3248806A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023150698A2 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119569893B (zh) * 2023-09-06 2025-10-31 上海恩凯细胞技术有限公司 特异性靶向肿瘤的嵌合抗原受体细胞及其制备方法和应用
CN119569892A (zh) * 2023-09-06 2025-03-07 上海恩凯细胞技术有限公司 特异性靶向肿瘤非经典hla分子的嵌合抗原受体的应用
CN119569891B (zh) * 2023-09-06 2025-09-05 上海恩凯细胞技术有限公司 用于癌症治疗的靶向非经典hla分子的嵌合抗原受体的应用
CN120248130B (zh) * 2023-12-28 2026-05-26 上海恩凯细胞技术有限公司 特异性靶向肿瘤的转基因重组免疫细胞及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201206559D0 (en) * 2012-04-13 2012-05-30 Ucl Business Plc Polypeptide
EP2730588A1 (en) 2012-11-12 2014-05-14 Intelectys Antibodies and fragments thereof raised against the alpha-3 domain of HLA-G protein, methods and means for their preparation, and uses thereof
WO2016065329A1 (en) * 2014-10-24 2016-04-28 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for inducing phagocytosis of mhc class i positive cells and countering anti-cd47/sirpa resistance
CA3025681A1 (en) 2016-06-03 2017-12-07 Invectys Anti hla-g specific antibodies
KR20180064612A (ko) * 2016-12-05 2018-06-15 삼성디스플레이 주식회사 표시 장치
BR112021003757A2 (pt) 2018-08-31 2021-05-25 Invectys SA receptores de antígenos quiméricos contra múltiplas isoformas de hla-g
US20200190163A1 (en) * 2018-10-26 2020-06-18 Lijun Wu Humanized bcma-car-t cells
KR102930430B1 (ko) * 2019-03-15 2026-02-26 카티전 테라퓨틱스, 인코포레이티드 항-bcma 키메라 항원 수용체
EP4010377A4 (en) 2019-08-09 2023-09-06 A2 Biotherapeutics, Inc. CELL SURFACE RECEPTORS THAT RESPOND TO LOSS OF HETEROZYGOSIS

Similar Documents

Publication Publication Date Title
CN112639102B (zh) 抗间皮素嵌合抗原受体(car)构建体及其用途
Pende et al. The natural killer cell receptor specific for HLA-A allotypes: a novel member of the p58/p70 family of inhibitory receptors that is characterized by three immunoglobulin-like domains and is expressed as a 140-kD disulphide-linked dimer.
EP3472205B1 (en) Chimeric antigen receptor
Koyasu et al. Delineation of a T-cell activation motif required for binding of protein tyrosine kinases containing tandem SH2 domains.
GB2611448A (en) Polypeptide useful in adoptive cell therapy
JP2023527049A5 (cg-RX-API-DMAC7.html)
JP2020511136A5 (cg-RX-API-DMAC7.html)
CN112074279A (zh) 人源化bcma抗体和bcma-car-t细胞
JP2020114264A5 (cg-RX-API-DMAC7.html)
US20200308248A1 (en) Chimeric Natural Killer Cell Receptors and Method of Using Thereof
JP2024502632A5 (cg-RX-API-DMAC7.html)
KR20170092695A (ko) 세포
KR20230095083A (ko) Cd7 표적의 키메라 항원 수용체 및 이의 용도
JP2021512615A5 (cg-RX-API-DMAC7.html)
KR102659440B1 (ko) 키메라 폴리펩티드 및 그의 세포 막 내 국재화를 변경시키는 방법
JP2018525006A5 (cg-RX-API-DMAC7.html)
JP2021532742A5 (cg-RX-API-DMAC7.html)
RU2018109426A (ru) Химерные антигенные рецепторы со встроенными контролируемыми функциями
KR20220166837A (ko) Nk억제 분자를 발현하는 조작된 면역 세포 및 그 용도
CN111542545A (zh) Cd38定向嵌合抗原受体构建体
KR20180131557A (ko) 면역요법에서의 tgf베타의 억제
JP2022545815A5 (cg-RX-API-DMAC7.html)
US12269861B2 (en) Chimeric ILT receptor compositions and methods
Wienands et al. Tyrosine-phosphorylated forms of Ig β, CD22, TCR ζ and HOSS are major ligands for tandem SH2 domains of Syk
JP2024534783A5 (cg-RX-API-DMAC7.html)